Equities analysts expect that Tcr2 Therapeutics Inc (NASDAQ:TCRR) will post earnings per share (EPS) of ($0.38) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Tcr2 Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.45) and the highest estimate coming in at ($0.34). The company is scheduled to issue its next earnings results on Monday, July 1st.

On average, analysts expect that Tcr2 Therapeutics will report full year earnings of ($1.94) per share for the current year, with EPS estimates ranging from ($2.08) to ($1.82). For the next year, analysts expect that the firm will report earnings of ($2.92) per share, with EPS estimates ranging from ($3.53) to ($2.58). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Tcr2 Therapeutics.

Tcr2 Therapeutics (NASDAQ:TCRR) last posted its quarterly earnings data on Monday, April 1st. The company reported ($16.22) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($15.84).

A number of analysts have recently issued reports on TCRR shares. BMO Capital Markets started coverage on shares of Tcr2 Therapeutics in a report on Monday, March 11th. They issued an “outperform” rating and a $37.00 price objective on the stock. Wedbush initiated coverage on shares of Tcr2 Therapeutics in a report on Monday, March 11th. They issued an “outperform” rating and a $28.00 price objective on the stock. They noted that the move was a valuation call. Svb Leerink initiated coverage on shares of Tcr2 Therapeutics in a report on Monday, March 11th. They set an “outperform” rating and a $27.00 target price on the stock. Jefferies Financial Group initiated coverage on shares of Tcr2 Therapeutics in a report on Monday, March 11th. They set a “buy” rating and a $31.00 target price on the stock. Finally, Leerink Swann initiated coverage on shares of Tcr2 Therapeutics in a report on Monday, March 11th. They set an “outperform” rating on the stock. Five analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average target price of $30.75.

In other news, Director Morana Jovan-Embiricos bought 666,667 shares of the stock in a transaction that occurred on Tuesday, February 19th. The shares were acquired at an average cost of $15.00 per share, for a total transaction of $10,000,005.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Upnorth Investment Ltd bought 200,000 shares of the stock in a transaction that occurred on Tuesday, February 19th. The shares were purchased at an average price of $15.00 per share, for a total transaction of $3,000,000.00. The disclosure for this purchase can be found here.

Shares of NASDAQ TCRR traded down $0.24 during midday trading on Monday, reaching $16.20. The company’s stock had a trading volume of 4,890 shares, compared to its average volume of 37,268. Tcr2 Therapeutics has a fifty-two week low of $14.80 and a fifty-two week high of $25.47. The company has a market capitalization of $390.94 million and a PE ratio of -0.16.

About Tcr2 Therapeutics

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.

Featured Article: Are FAANG stocks a good investment?

Get a free copy of the Zacks research report on Tcr2 Therapeutics (TCRR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.